Benchmark Maintains Speculative Buy on Harvard Bioscience, Lowers Price Target to $3
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
Benchmark analyst Bruce Jackson maintains Harvard Bioscience (NASDAQ:HBIO) with a Speculative Buy and lowers the price target from $4.5 to $3.
Benchmark analyst Bruce Jackson maintains Harvard Bioscience (NASDAQ:HBIO) with a Speculative Buy and lowers the price target from $4.5 to $3.